Potential of DEK proto-oncogene as a prognostic biomarker for colorectal cancer: An evidence-based review

Muhammad Habiburrahman, Muhammad Prasetio Wardoyo, Stefanus Sutopo, Nur Rahadiani

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Given its role in tumorigenesis and its correlation with various pathologic features of colorectal cancer (CRC), DEK is considered to have the potential to predict CRC prognosis. This review at t empt s t o summar i ze current knowledge and evidence supporting the potential of DEK as a prognostic biomarker of CRC. We searched met a-analyses, systematic reviews, cohor t st udies, and cell line studies published in the last 10 years. A literature search was conducted in PubMed, Pubmed Central (PMC), Proquest, EBSCOHost, Scopus, and Cochrane Librar y using the keywords ‘colorectal/colon/rectal cancer’, ‘DEK’, ‘biomarker’, and ‘prognosis’. Studies that were not published in English, without accessible full text, unrelated to clinical questions, or conducted with a design unsuitable for the eligibility criteria were excluded. Seven included studies reported the potential of DEK as a prognostic biomarker of CRC and its role in cancer cell proliferation, invasion, and metastasis. This role is achieved through the Wnt/β-catenin pathway, prevention of apoptosis through destabilization of p53, and bridging inflammation and tumorigenesis through t he nuclear factor ( NF)-κB pat hway, causi ng chronic inf lammation and activation of tumorigenic genes. DEK overexpression is also associated with CRC clinical and pathological features, such as tumor size, lymph node metastasis, serosal invasion, differentiation, tumor staging, and epithelial-mesenchymal transition. DEK overexpression was found to be associated with lower survival and recovery rates. Its prognostic value was comparable with other prognostic biomarkers of CRC, such as BRAF, topoisomerase-1, and CEA. A cohort study reported that DEK overexpression was associated with a better response to fluoropyrimidine-based chemotherapy, while a cell-line study indicated a correlation between DEK overexpression with a worse response to irinotecan-based chemotherapy. In conclusion, considering its correlation with CRC pathology, its association with worse CRC patient survival, and its possibility to forecast the therapeutic response of various chemotherapeutic regimens, DEK has the potential to be used as a CRC prognostic biomarker.

Original languageEnglish
Article number117
JournalMolecular and Clinical Oncology
Issue number1
Publication statusPublished - 1 Jul 2022


  • biomarker
  • chemotherapy
  • colorectal cancer
  • DEK
  • prognosis
  • survival


Dive into the research topics of 'Potential of DEK proto-oncogene as a prognostic biomarker for colorectal cancer: An evidence-based review'. Together they form a unique fingerprint.

Cite this